SPOTLIGHT: NICE rejects Roche drug as too costly


Roche's lung cancer med Tarceva got the goodbye gong from the U.K.'s National Institute for Clinical Excellence, which ruled that the drug wasn't a cost-effective option for treating non-small cell lung cancer. Roche said it would appeal as patient advocacy groups assailed NICE's decision. Report